

**QT VASCULAR LTD.**  
(Company Registration No.: 201305911K)  
(Incorporated in Republic of Singapore)

---

**UPDATE ON THE POTENTIAL LEGAL PROCEEDINGS WITH INNORA GMBH**

---

*Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meaning ascribed to them in the Company's previous announcements dated 27 August 2020 and 30 August 2021 which highlighted the InnoRa Dispute.*

The Board of Directors of QT Vascular Ltd. (the "**Company**", and together with its subsidiaries, "**Group**") would like to update that on 13 October 2021, the Company's wholly owned subsidiaries, TriReme Singapore Pte Ltd and Quattro Vascular Pte Ltd, had filed for a demand for arbitration against InnoRa GmbH ("**InnoRa**") with the American Arbitration Association's San Francisco regional office, seeking declaratory judgements and damages of not less than USD1,000,000 from InnoRa ("**Notice of Arbitration**").

For the avoidance of doubt, InnoRa has not responded to the Notice of Arbitration nor commenced any formal legal proceedings against TriReme Medical LLC as at the date of this announcement.

The Company will update the Shareholders as and when there are any material updates to the aforementioned arbitration, including its financial effects on the Group.

**BY ORDER OF THE BOARD**

Eitan Konstantino  
Chief Executive Officer  
18 October 2021

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.*